Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Silo Pharma Inc. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 3 distinct art units, indicating a relatively broad prosecution landscape. This distribution suggests that the company's intellectual property covers several technical sub-fields within the biotechnology sector. Managing such a spread requires a strategy that accounts for the different procedural norms and technical expertise found across the 3 distinct art units. Practitioners must navigate varied examination styles as they address the unique requirements of each assigned unit.
KETCHAM, KAREN A is identified as the busiest examiner, although she is responsible for only 1 pending office action. Because the 4 pending actions are split among 4 different examiners, no single individual dominates the current workload. This lack of concentration requires the legal team to monitor multiple examiner histories and art unit precedents simultaneously. Successfully advancing the portfolio will require a nuanced approach that addresses the specific concerns raised within each of the 3 distinct art units. The diverse nature of the current prosecution suggests a need for broad technical expertise across the pharmaceutical filings.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 1 | 21.1% | +39.9% |
| PEEBLES, KATHERINE | 1 | 35.5% | +47.3% |
| BROWE, DAVID | 1 | 26.8% | +27.8% |
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257014 | USE OF PSILOCYBIN IN CANCER TREATMENT | KETCHAM, KAREN A | 59d overdue |
| 18004400 | CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN | ROSSI, JULIA ANNE LORRAIN | 84d |
| 18004546 | CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN | BROWE, DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004633 | CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | PEEBLES, KATHERINE | 60d overdue |
| 18257014 | USE OF PSILOCYBIN IN CANCER TREATMENT | KETCHAM, KAREN A | 59d overdue |
| 18004400 | CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN | ROSSI, JULIA ANNE LORRAIN | 84d |
| 18004546 | CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN | BROWE, DAVID | — |
| Art Unit | Apps |
|---|---|
| 1617 | 2 |
| 1614 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257014 | USE OF PSILOCYBIN IN CANCER TREATMENT | KETCHAM, KAREN A | 1614 | §103DP | Final Rejection | 59d overdue | Pending | Jun 12, 2023 |
| 18004633 | CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | PEEBLES, KATHERINE | 1617 | §103§112DP | Non-Final OA | 60d overdue | Pending | Jan 06, 2023 |
| 18004546 | CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN | BROWE, DAVID | 1617 | §103§112Other | Final Rejection | — | Pending | Jan 06, 2023 |
| 18004400 | CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Final Rejection | 84d | Pending | Jan 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSilo Pharma Inc. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.
Karen A Ketcham has the most, with 1 of Silo Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.